Please assess the completion status of the following clinical trial:

Trial Title: Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1.Patients 18 years of age or older with a new or existing diagnosis of cancer with a CVC inserted within the last 72 hours.~Exclusion Criteria:~1. CVC in place for \>72 hours~2. Patient requires anticoagulation for other indication~3. Concomitant use of dual antiplatelet therapy~4. Prior VTE~5. Major bleeding event in the last 6 weeks~6. Patient on concomitant medication with known interaction with rivaroxaban (eg. CYP3A4 inhibitor)~7. Pregnancy (documentation of use of effective contraception if sexually active or negative B-Hcg required)~8. Known renal failure, based on Creatinine clearance \<30 mL/min (Cockcroft-Gault) (in the previous 3 months)~9. Documented severe liver disease (eg. acute clinical hepatitis, chronic active hepatitis, cirrhosis or ALT \>3ULN) ( in the previous 3 months)~10. Known thrombocytopenia \< 50x 109/L (in the previous 3 months)~11. Allergy to rivaroxaban~12. Life expectancy \<6 months~13. History of condition at increased bleeding risk including, but not limited to:~    1. Major surgical procedure or trauma within 30 days before the randomization visit~   2. Clinically significant gastrointestinal bleeding within 6 months before the randomization visit~   3. History of intracranial, intraocular, spinal, or atraumatic intra-articular bleeding~   4. Chronic hemorrhagic disorder~   5. Known intracranial neoplasm, arteriovenous malformation, or aneurysm~   6. Sustained uncontrolled hypertension: systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg~14. Primary malignancy diagnosis of basal cell or squamous cell carcinoma of the skin or acute leukemia or myelodysplastic syndrome~15. Geographic inaccessibility~16. Refused or unable to obtain consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban Thromboprophylaxis (Type: EXPERIMENTAL): Rivaroxaban 10 mg po daily for 90 days(+/- 3 days). After the Day - 90 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.
- Standard of care (Type: NO_INTERVENTION): No rivaroxaban prophylaxis. Management will be at the discretion of the attending physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).